The pharma wins US approval for a new rheumatoid arthritis pill, but Abbott's existing treatment isn't likely to suffer a meaningful hit to sales anytime soon.
These undervalued equities offer rapid growth potential and strong finances.
Right now it may be the main thing that's propping up shares of the gene sequencing company.
The company raises sales guidance while reporting better-than-expected Q3 earnings.
Although Abbott has recently gained on positive trial results, Gilead Sciences remains in the forefront of the market.
Analyst predicts it will take time, however, before Qsymia records meaningful revenue.
These solid, dividend-paying stocks are well-suited to a buy-and-hold strategy.
VIDEO ON MSN MONEY
Copyright © 2013 Microsoft. All rights reserved.
Quotes are real-time for NASDAQ, NYSE and AMEX. See delay times for other exchanges.
Fundamental company data and historical chart data provided by Thomson Reuters (click for restrictions). Real-time quotes provided by BATS Exchange. Real-time index quotes and delayed quotes supplied by Interactive Data Real-Time Services. Fund summary, fund performance and dividend data provided by Morningstar Inc. Analyst recommendations provided by Zacks Investment Research. StockScouter data provided by Verus Analytics. IPO data provided by Hoover's Inc. Index membership data provided by SIX Financial Information.
The Market Dispatches column has been discontinued. Here's where to find the latest stock and business news on MSN Money, and the latest from market writer Charley Blaine.
MONEY & POLITICS
Breaking up big banks is an untested solution to the too big to fail problem that attempts to isolate and dismantle large, troubled institutions while protecting the rest of the economy.
New York's mayor says a composting program would save millions. It's a great frugal hack for anybody, anywhere. Here's how to get started.
The IRS is struggling to combat identify thieves who file fraudulent tax returns in the names of older residents who don't need to file.